The Science of SLD and Dysmetabolism-Session 5: Q&A

Video Transcription

Video Summary

Panelists discuss evidence gaps and priorities around maternal diet, childhood obesity, and MASLD/MASH risk. A question about mothers drinking sugar-sweetened beverages and later child obesity/diabetes highlights limited direct data, though speakers emphasize developmental “programming” from in-utero metabolic exposure (e.g., gestational diabetes showing early liver changes). Another discussion frames a “tsunami” of pediatric obesity/MASLD: effective care likely requires whole-family, multidisciplinary interventions; broader environmental and policy changes (school food standards, advertising restrictions) are also urged. GLP-1 therapies are viewed as promising but underused in adolescents; discontinuation often leads to weight regain, though some benefit persists, and longer or micro-dosed treatment may help—yet true “resetting” is uncertain. For MASLD natural history, speakers note heterogeneous patient “buckets” but no reliable way yet to predict who will progress; future risk stratification may combine advanced imaging and serum/lipidomic biomarkers, with fibrosis markers currently most actionable. In pregnancy, FibroScan/transient elastography is considered safe, though trajectories across pregnancy/postpartum remain unclear. Ultra-processed food classification (NOVA) is debated as too broad; nutrient quality and additives matter.

Keywords

maternal diet and fetal programming

pediatric obesity and MASLD/MASH

sugar-sweetened beverages and child metabolic risk

family-based multidisciplinary obesity interventions

GLP-1 receptor agonists in adolescents

MASLD progression risk stratification biomarkers and imaging